Contact this trialFirst, we need to learn more about you.
Chelating Agent
ALXN1840 +1 More for Wilson's Disease
Recruiting2 awardsPhase 3
Chicago, Illinois
This trial tests ALXN1840, a new medicine for Wilson Disease, in patients aged 12 and older. It aims to see if it works better than usual treatments by helping remove excess copper from the body. ALXN1840 is a new treatment for Wilson Disease, which traditionally involves chelation therapy to remove excess copper.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service